Tandem Health, a Stockholm-based digital health company building an AI medical assistant for clinical documentation, has raised $100 million in Series B funding led by the Scaleup Europe Fund, managed by EQT, the company announced on September 14, 2026. The round brings Tandem's total funding to $160 million, per company statements.
What did the round actually involve?
The Scaleup Europe Fund, which targets 5 billion euros across deeptech, AI and life sciences and combines public and private capital, made Tandem the first healthcare AI company it has backed, according to the company's announcement. Existing investors Kinnevik, Northzone, Amino Collective and Visionaries also participated. The Series B follows a $50 million Series A in 2025, per coverage of the round. A valuation for the new round was not yet disclosed.
The company said the capital will fund two priorities: deepening its position as an AI partner to European care providers, and growing from a documentation assistant into what it calls an AI-native clinic operating system covering patient flow, triaging, scheduling and patient communications. Tandem says it has offices in 14 European markets, that its product is used by more than 10,000 care organisations including Ramsay Sante, Humanitas and the NHS, and that it is supported by a team of 100 in-house clinicians — all company-claimed figures.
What does the published evidence behind the product show?
The most substantial public dataset on the product's effect is a peer-reviewed evaluation of an AI medical scribe after 236,153 notes generated across care levels in a European health system, published in JMIR Medical Informatics and listed on the company's research page. In the study's primary outcome, self-reported documentation time per note was 4.72 minutes with the scribe versus 6.69 minutes without — a 29% decrease (P<.001) — among 1,295 clinicians at Capio Ramsay Sante in Sweden.
The limitations matter as much as the headline figure. The evaluation was a single-arm observational study with a self-selected cohort of fully onboarded users, and two authors were Tandem Health employees, with co-author Lukas Saari the company's chief executive; the paper states that statistical analyses were performed by an academic coinvestigator with no vendor affiliation. On certification, the company states it is the only AI medical assistant whose scribe, coding assistant and clinical decision support tools are each independently certified as Class IIa devices under the EU Medical Device Regulation — a company claim.
Why does the round matter for European clinical AI?
The financing is one of the largest European digital health rounds of the year and an early marker of where public-private capital is pointing: sovereign European infrastructure for healthcare AI rather than imported platforms. Tandem says data stays in Europe under a sovereign architecture, and the round gives the company runway to move up the stack from documentation — a workflow with a growing evidence base — into scheduling, triage and patient communication, where published outcome evidence is thinner.
This article is industry news coverage and is not medical advice. Nothing here should be used to make decisions about medical care or treatment.
